What is Aeromics?
Aeromics, Inc. operates at the intersection of advanced water physiology and neurology, focusing on the development of therapeutics that target aquaporin-4 (AQP4) channels. The company's flagship asset, AER-271, is engineered to mitigate brain swelling in patients experiencing severe ischemic stroke. By addressing the underlying mechanisms of cerebral edema, Aeromics aims to redefine standard-of-care protocols for acute neurological trauma. The company is currently navigating the complex regulatory landscape of clinical trials, transitioning from initial safety assessments to efficacy-focused Phase II studies. This clinical-stage trajectory positions Aeromics as a high-potential player in the biopharmaceutical sector, specifically within the high-acuity stroke management market.
How much funding has Aeromics raised?
Aeromics has raised a total of $13.3M across 5 funding rounds:
Grant
$2.3M
Private Equity
$1.3M
Debt
$1.9M
Debt
$1.5M
Private Equity
$6.4M
Grant (2009): $2.3M with participation from National Institutes of Health
Private Equity (2014): $1.3M, investors not publicly disclosed
Debt (2016): $1.9M, investors not publicly disclosed
Debt (2017): $1.5M, investors not publicly disclosed
Private Equity (2017): $6.4M, investors not publicly disclosed
Key Investors in Aeromics
National Institutes of Health
The National Institutes of Health is the primary agency of the United States government responsible for biomedical and health-related research, providing critical non-dilutive funding for early-stage medical innovation.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Aeromics?
The recent influx of capital provides the necessary runway for Aeromics to accelerate its clinical development roadmap. Strategic priorities include the successful completion of Phase 1 safety trials and the subsequent initiation of Phase II efficacy studies for AER-271. As the company matures, it is expected to leverage its deep expertise in water physiology to explore additional indications for its AQP4-targeting platform. Future growth will likely be defined by the company's ability to demonstrate clinical efficacy in human subjects, potentially setting the stage for strategic partnerships with larger pharmaceutical entities or further equity financing rounds to support commercialization efforts.
See full Aeromics company page
